The IRE Resource Center is a major research library containing more than 27,000 investigative stories.
Most of our stories are not available for download but can be easily ordered by contacting the Resource Center directly at 573-882-3364 or firstname.lastname@example.org where a researcher can help you pinpoint what you need.
Search results for "Pharmaceutics" ...
I exposed a concerted and well-funded campaign by the country’s leading pharmaceutical companies to defeat bills in Congress and state legislatures that were aimed at stopping the spread of toxic methamphetamine labs. At issue? Pseudoephedrine sales. The popular decongestant is the one key ingredient needed to make homemade meth. It also generates revenue for major pharmaceutical firms such as Pfizer, Johnson & Johnson, and Merck of more than $600 million a year. Fuelled by easy access to pseudoephedrine, the number of meth labs in the United States has increased by more than 60 percent since 2007. Thanks in large part to pharmaceutical industry lobbying, there has been no federal legislation to address the spread of meth labs since 2005. In 2006, Oregon successfully moved to restrict meth cooks’ access to pseudoephedrine by making it a prescription drug, despite heavy lobbying against the bill from the pharmaceutical industry. Since then, the number of meth labs in the state has fallen drastically—by more than 90 percent. Faced with the mounting social, law enforcement, and environmental costs associated with meth, legislators in at least 25 other states sought to pass similar laws. But pharmaceutical lobbyists fought back, and in all but one state—Mississippi—the bills were defeated. My reporting examined how the industry has set state lobbying spending records as it has deployed a new kind of lobbying strategy to block regulation of pseudoephedrine. Instead of focusing their efforts on courting politicians, they have taken their message directly to voters, deploying thousands of robocalls in key electoral districts and large ad buys in major media markets for advertising across multiple platforms from radio to the Internet. Their messaging, I found, was deceptive, failing to even mention that the proposed bills had to do with combatting the meth epidemic. I also examined the results of an electronic pseudoephedrine sales tracking database known as NPLEx, which is meant to prevent excessive purchasing. While it’s the only reform to ever earn backing from the pharmaceutical industry, I found a system full of holes that has been ineffective at preventing the spread of meth labs in virtually every state that has adopted it.